Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) — […]
Author: Ken Dropiewski
BioSig Announces Closing of Public Offering of Common Stock
Westport, CT, Feb. 25, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the closing and funding of […]
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
CONSHOHOCKEN, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development of resmetirom. We initiated two Phase 3 studies in NASH: […]
Foldax Tria LifePolymer Heart Valve Technology Honored with Best Innovation Award at 2020 Cardiovascular Research Technologies Meeting
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that Tria LifePolymer™ heart valve technology was honored with The Best Innovation Award at the 2020 Cardiovascular Research Technologies (CRT) meeting in National Harbor, MD. The presentation, titled “Foldax Tria First in Human Implant of a Totally Synthetic Polymeric Aortic Heart Valve,” was given […]
Zynex Receives FDA Clearance for its Blood Volume Monitor
ENGLEWOOD, Colo., Feb. 25, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the U.S. Food and Drug Administration (“FDA”) granted 510(k) clearance for sale in the U.S. for […]
Artio Medical Announces Appointment of Maria Sainz to Board of Directors
FAIRWAY, Kan., Feb. 25, 2020 /PRNewswire/ — Artio Medical, Inc (Artio), a medical device company developing innovative products for peripheral vascular and neurovascular diseases, announced today the appointment of seasoned medical device industry executive Maria Sainz to its Board of Directors as an independent director. Sainz is currently the President and CEO of AEGEA Medical, a venture […]
Aria CV Announces $31 Million in Series B Funding
Funding to support the Aria CV Pulmonary Hypertension System Feasibility Study Financing led by Xeraya Capital ST. PAUL, Minn.–(BUSINESS WIRE)–Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that it has completed a $31 million Series B round of financing to fund its first […]
Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification […]
Hemostemix Announces Corporate Update
CALGARY, Alberta, Feb. 25, 2020 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) provides the following update: On February 21, 2020, the Court Queen’s Bench of Alberta (the “Court”), after having heard the concerns raised by the Company with respect to an application by J.M. […]
Merit Medical Reports Earnings for Fourth Quarter and Year Ended December 31, 2019, Gives FY 2020 Guidance
Q4 2019 worldwide revenue of $257.9 million, up 10.6% as reported over Q4 2018 Q4 2019 core revenue on a comparable, constant currency basis* up 8.5% over Q4 2018 Q4 2019 GAAP loss per share was $(0.08), compared to GAAP EPS of $0.16 in Q4 2018 Q4 2019 non-GAAP EPS* […]


